One of many firm’s wholly-owned subsidiaries has entered right into a license settlement with Ferring Prescribed drugs Pvt Ltd — a subsidiary of Switzerland-based Ferring Prescribed drugs — to commercialise a room temperature secure formulation of the obstetric drug Caritec in India, Solar Pharma stated in a regulatory submitting.
The drug is indicated for the prevention of extreme bleeding in ladies after vaginal or caesarean childbirth, it added.
As per the settlement, Solar Pharma is granted rights for co-marketing of the drug in India within the non-public market beneath the model title Caritec.
Ferring has developed the drug and obtained approval from the Medication Controller Common of India (DCGI) for introducing the medication in India, Solar Pharma stated.
“By our collaboration with Ferring, we’re introducing an modern medication that may assist in lowering 1000’s of deaths from postpartum haemorrhage (PPH) yearly,” Solar Pharma India enterprise CEO, Kirti Ganorkar stated.
PPH is a number one reason behind maternal mortality worldwide and in nations like India. Postpartum bleeding is a largely preventable and manageable situation, the assertion stated.
Shares of Solar Pharmaceutical Industries closed at Rs 677.65 per scrip on BSE, up 0.95 per cent from its earlier shut.